Condition: Unresectable or Metastatic Advanced Pancreatic Ductal Adenocarcinoma · Sponsor: John Lenehan
To confirm the safety of combining oral fecal microbiota transplantation (FMT) with gemcitabine and nab-paclitaxel chemotherapy as first line treatment in patients with unresectable or metastatic pancreatic ductal adenocarcinoma.
This description comes directly from the study's public registry record.
John G Lenehan, MD · 519-685-8640 · John.Lenehan@lhsc.on.ca
Always discuss trial participation with your own doctor first.
| Verspeeten Family Cancer Centre (formerly known as the London Regional Cancer Program) London Health Sciences Centre | London, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06393400